Flubromazolam (JYI-73) is a novel synthetic depressant substance of the benzodiazepine, and specifically, the triazolobenzodiazepine class which produces anxiolytic, disinhibiting, sedative, muscle relaxant, and memory suppressing effects when administered. It is incredibly potent (active in the microgram range) with an unusually long 18 hour duration. Thus, it poses comparatively higher risks than other designer benzodiazepines, due to its ability to produce strong sedation and amnesia even at a very low threshold dosage.
Flubromazolam has been noted for its potential use in the short-term treatment of anxiety, insomnia, acute seizures, and the sedation of hospitalized patients. However, it is currently exclusively sold by online research chemical vendors for use as a recreational psychoactive substance and has not been formally studied, first being definitively identified in 2017.